{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-082783","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2025-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.323213+00:00","generated_at":"2026-05-17T09:53:32.564493+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"confidence":"high","headline":"Marker Therapeutics Phase 1 APOLLO data: 66% ORR in NHL; 50% CR; dose expansion cleared","bullets":["66% objective response rate in NHL patients (8/12), with 50% complete response (6/12) at doses 100-200×10^6 cells.","No dose-limiting toxicities or ICANS observed; two Grade 1 CRS events (no treatment required).","Safety Review Committee cleared 400×10^6 cells max dose for DLBCL dose expansion in CAR-T relapsed/ineligible patients.","HL patients (n=9) showed 78% ORR (7/9) with 11% CR; median 8 prior lines of therapy.","Webcast August 26, 2025 at 8:30 am ET; next data update expected H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-082783","json":"https://secwatch.observer/filing/0001104659-25-082783.json","markdown":"https://secwatch.observer/filing/0001104659-25-082783.md","text":"https://secwatch.observer/filing/0001104659-25-082783.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925082783/0001104659-25-082783-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925082783/tm2524197d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:53:32.564493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}